Griseofulvin

Griseofulvin (GF) is a mycotoxin produced by various species of Penicillium including P. griseofulvum Dierckx, P. janczewski (P. nigricans) and P. patulum. It is active against dermatophytic fungi of different species in the genera Microsporum, Trychophyton and Epidermophyton. Because of its capacity to concentrate in the keratinous layer of the epidermis and its relatively low toxicity in man, it has been extensively used in the therapy of dermatophytoses by oral administration. The biological activity of GF towards fungi is manifested as nuclear and mitotic abnormalities followed by distortions in the hyphal morphology. Mitotic segregation is also induced in fungi by GF treatment. In higher eukaryotes the cytostatic action of GF is essentially due to a mitotic arrest at late metaphase/early anaphase. The cytological effects observable both in vivo and in vitro on different plant and animal cell systems, include C-mitoses, multipolar mitoses and multinuclearity. Prolonged GF treatment in experimental animals provokes biochemical changes consisting mainly of disturbances of porphyrin metabolism, variation in the microsomal cytochrome levels and formation of Mallory bodies. In mice these alterations are followed by the development of multiple hepatomas. Evidence of tumor induction by GF has been obtained in mice and rats, but not in hamsters. GF may also act either as a promoting or a co-carcinogenic agent, depending on the circumstances of its administration. It has been found to increase the frequency of cell transformation induced by polyoma virus, but not to induce cell transformation per se. Induction of sperm abnormalities has been observed in GF-treated mice. The embryotoxic and teratogenic action of GF has been demonstrated in pregnant rats exposed during organogenesis. Genetic effects of GF have been investigated by the following tests: Salmonella/microsome mutagenicity assay, point mutations in mammalian and plant cells, DNA damage and repair, SCE, chromosome aberrations, micronuclei, dominant lethals, aneuploidy in lower and higher eukaryotes. A positive response has been obtained in the assays on numerical chromosome changes in all the systems analyzed; limited or inconclusive evidence has been obtained for SCE and structural chromosome changes. Doubled or highly polyploid sets can be detected in all types of cells during or immediately after GF treatment. A marked increase in chromosome number variation is observed at various times after withdrawal of the drug, with prevailing hyperdiploid and reduced sets in animal cells and plant cells respectively.(ABSTRACT TRUNCATED AT 400 WORDS)     

Griseofulvin

Griseofulvin (GF) is a mycotoxin produced by various species of Penicillium including P. griseofulvum Dierckx, P. janczewski (P. nigricans) and P. patulum. It is active against dermatophytic fungi of different species in the genera Microsporum, Trychophyton and Epidermophyton. Because of its capacity to concentrate in the keratinous layer of the epidermis and its relatively low toxicity in man, it has been extensively used in the therapy of dermatophytoses by oral administration. The biological activity of GF towards fungi is manifested as nuclear and mitotic abnormalities followed by distortions in the hyphal morphology. Mitotic segregation is also induced in fungi by GF treatment. In higher eukaryotes the cytostatic action of GF is essentially due to a mitotic arrest at late metaphase/early anaphase. The cytological effects observable both in vivo and in vitro on different plant and animal cell systems, include C-mitoses, multipolar mitoses and multinuclearity. Prolonged GF treatment in experimental animals provokes biochemical changes consisting mainly of disturbances of porphyrin metabolism, variation in the microsomal cytochrome levels and formation of Mallory bodies. In mice these alterations are followed by the development of multiple hepatomas. Evidence of tumor induction by GF has been obtained in mice and rats, but not in hamsters. GF may also act either as a promoting or a co-carcinogenic agent, depending on the circumstances of its administration. It has been found to increase the frequency of cell transformation induced by polyoma virus, but not to induce cell transformation per se. Induction of sperm abnormalities has been observed in GF-treated mice. The embryotoxic and teratogenic action of GF has been demonstrated in pregnant rats exposed during organogenesis. Genetic effects of GF have been investigated by the following tests: Salmonella/microsome mutagenicity assay, point mutations in mammalian and plant cells, DNA damage and repair, SCE, chromosome aberrations, micronuclei, dominant lethals, aneuploidy in lower and higher eukaryotes. A positive response has been obtained in the assays on numerical chromosome changes in all the systems analyzed; limited or inconclusive evidence has been obtained for SCE and structural chromosome changes. Doubled or highly polyploid sets can be detected in all types of cells during or immediately after GF treatment. A marked increase in chromosome number variation is observed at various times after withdrawal of the drug, with prevailing hyperdiploid and reduced sets in animal cells and plant cells respectively. Closely related to the effect on chromosome number is the ability of GF to increase the frequency of segregants for selected genetic markers in different cell systems either in the presence or in the absence of mutagenic treatment.The mode of action of GF on mitotic spindle microtubules (MTs) has been analyzed in comparison with other known antitubulins. Unlike colchicine and Vinca alkaloids GF causes a reduction or disruption of MTs, in relation to the dose, by inhibiting their combination with the microtubule-associated proteins (MAPs). Evidence in favor of this kind of interaction is provided by the results of studies on GF-resistant mutants in mammalian cells.In view of its unique properties as a microtubule-disorganizing agent, its capacity to induce chromosome malsegregation in a variety of organisms either in vivo or in vitro and its specific effects on liver metabolism, GF may be considered a valuable research antibiotic. Major reservations on its therapeutic use seem to be justified when considering the positive response to carcinogenicity and teratogenicity tests in animals and the chromosome effects observed both in vivo and in vitro.     

Enhanced Oral Bioavailability of Griseofulvin via Niosomes

The aim of the present report was to develop nonionic surfactant vesicles (niosomes) to improve poor and variable oral bioavailability of griseofulvin. Niosomes were prepared by using different nonionic surfactants span 20, span 40, and span 60. The lipid mixture consisted of surfactant, cholesterol, and dicetyl phosphate in the molar ratio of 125:25:1.5, 100:50:1.5, and 75:75:1.5, respectively. The niosomal formulations were prepared by thin film method and ether injection method. The influence of different formulation variables such as surfactant type, surfactant concentration, and cholesterol concentration was optimized for size distribution and entrapment efficiency for both methods. Result indicated that the niosomes prepared by thin film method with span 60 provided higher entrapment efficiency. The niosomal formulation exhibited significantly retarded in vitro release as compared with free drug. The in vivo study revealed that the niosomal dispersion significantly improved the oral bioavailability of griseofulvin in albino rats after a single oral dose. The maximum concentration (C _max) achieved in case of niosomal formulation was approximately double (2.98 μg/ml) as compared to free drug (1.54 μg/ml). Plasma drug profile also suggested that the developed niosomal system also has the potential of maintaining therapeutic level of griseofulvin for a longer period of time as compared to free griseofulvin. The niosomal formulation showed significant increase in area under the curve_0-24 (AUC; 41.56 μg/ml h) as compared to free griseofulvin (22.36 μg/ml h) reflecting sustained release characteristics. In conclusion, the niosomal formulation could be one of the promising delivery system for griseofulvin with improved oral bioavailability and prolonged drug release profiles.     

灰黄霉素菌的诱变效应

以灰黄霉素产生菌D－756为出发菌株,经过三代紫外线＋氯化锂诱变处理,获得耐氯变株F－1012,该变株在形态特征及产量、耐氯性等方面均发生变化,当发酵培养基中的氯化物浓度由1.5%提高到2.0%,F－1012的大米孢子效价提高了34.5%;当固体平板培养基中氯化物浓度提高到11％时,F－1012的孢子存活率比出发菌株提高了25.5％。     

ONYCHOMYCOSIS OF THE FEET—Treatment with Griseofulvin

Griseofulvin, a new orally administered antifungal antibiotic which has proved to be effective for the treatment of a wide variety of superficial fungus infections of man, was used in the treatment of 51 patients with infections of the toenails due to T. rubrum. Thirty-four of the patients were treated with griseofulvin alone and seven were treated with griseofulvin combined with surgical avulsion of all involved toenails. The remaining ten had bilateral infections, and avulsion was done on one foot but not the other before griseofulvin therapy was begun.Of 34 patients who were treated with griseofulvin alone, few had complete cure even after prolonged treatment. Some nails showed improvement for a time, then no further gain; some showed no improvement; some showed resistant wedges of infection which penetrated proximally toward the posterior nail fold.In the instances of surgical avulsion, clinically normal nails regrew during griseofulvin therapy. This simple procedure, with thorough removal of all underlying keratinous debris, apparently did away with foci of possible reinfection.The results of the study indicated that surgical avulsion of the toenails in combination with griseofulvin therapy is an effective and practical method of treating onychomycosis of the toenails due to T. rubrum.